Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris

Next Previous
Trial Profile

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DSG3-CAART (Primary) ; Resecabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine; Immune globulin
  • Indications Pemphigus vulgaris
  • Focus Adverse reactions; First in man
  • Acronyms DesCAARTes; RESET-PV
  • Sponsors Cabaletta Bio

Most Recent Events

  • 10 Nov 2025 According to a Cabaletta Bio media release, company is expanding patient enrollment in the RESET-PV trial at the current dose, with the potential to evaluate higher doses.
  • 09 Oct 2025 Results published in the Media Release
  • 09 Oct 2025 According to a Cabaletta Bio media release, company announced that data are being presented in a late-breaking clinical oral presentation by Samik Basu, M.D., Chief Scientific Officer at Cabaletta, at the ongoing 2025 European Society of Gene & Cell Therapy (ESGCT) Annual Congress, which is being held in Seville, Spain, from October 7-10, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top